about
Small molecules targeting viral RNAMetal-binding and redox properties of substituted linear and cyclic ATCUN motifs.Hepatitis C virus translation inhibitors targeting the internal ribosomal entry site.Insight into the recognition, binding, and reactivity of catalytic metallodrugs targeting stem loop IIb of hepatitis C IRES RNAAnalysis of RNA cleavage by MALDI-TOF mass spectrometry.The potent oxidant anticancer activity of organoiridium catalysts.Kinetics and Mechanisms of Oxidative Cleavage of HIV RRE RNA by Rev-Coupled Transition Metal ChelatesTransfer hydrogenation catalysis in cells as a new approach to anticancer drug design.Toward the design of a catalytic metallodrug: selective cleavage of G-quadruplex telomeric DNA by an anticancer copper-acridine-ATCUN complexCatalytic metallodrugs based on the LaR2C peptide target HCV SLIV IRES RNA.Antimicrobial metallopeptides with broad nuclease and ribonuclease activity.Target-directed catalytic metallodrugs.Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.Analysis of Structure-Activity Relationships Based on the Hepatitis C Virus SLIIb Internal Ribosomal Entry Sequence RNA-Targeting GGHYRFK⋅Cu Complex.Drastic effect of the peptide sequence on the copper-binding properties of tripeptides and the electrochemical behaviour of their copper(II) complexes.Metal complexes promoting catalytic cleavage of nucleic acids-biochemical tools and therapeutics.Catalytic Metallodrugs: Substrate-Selective Metal Catalysts as Therapeutics.N-terminal Cu Binding Motifs Xxx-Zzz-His (ATCUN) and Xxx-His and their derivatives: Chemistry, Biology and Medicinal Applications.Enhanced stability of Cu(2+)-ATCUN complexes under physiologically relevant conditions by insertion of structurally bulky and hydrophobic amino acid residues into the ATCUN motif.
P2860
Q26745817-D89C98B2-3273-42F9-977F-271A8D0FCD40Q33993654-11C5E879-F992-4FAF-933B-D57FC4597687Q34038589-76989272-A234-4497-BDB6-A4536241FC82Q34174821-396E3C60-2EA4-4586-9680-17562250D617Q34401347-5F3B17A0-D17E-45D8-91E2-2AA989D2EF66Q34488624-2D53EABC-DDD6-4726-8521-676DE0D9264DQ34693492-66DDC01D-5BF2-4FE8-B442-46154E8F3B3BQ35247064-9346B294-6247-428D-9A9E-03B98BDB4830Q35518250-CEFD5F21-0BE5-4478-89B2-57ECC3D3ECB0Q35846078-4653B3D4-61FD-4F9D-BE60-93920CB81921Q36784571-D610EE90-2097-4DF8-B486-90A9E5E3F8F3Q37371607-C91A9125-AFE8-43F8-A1FD-04EF1F1A23E8Q38011996-A40A10E5-9EB7-48D6-B294-345B543ABA60Q38669304-E60E2839-1C44-4797-ABFF-768FCC6CF1B2Q46250167-42D24650-591B-4DC9-80F7-A6B44CD70795Q47831091-8DB53048-3E11-46B4-B75A-0E2299ECE45FQ48157762-129493A5-235F-4C29-A8A7-CED4CE66F448Q50036711-AD1222F7-112B-46B4-A81F-04C813A33682Q54630025-85ED3AC3-1AA3-4843-B949-08C0416B70F1
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Catalytic metallodrugs targeting HCV IRES RNA.
@en
Catalytic metallodrugs targeting HCV IRES RNA.
@nl
type
label
Catalytic metallodrugs targeting HCV IRES RNA.
@en
Catalytic metallodrugs targeting HCV IRES RNA.
@nl
prefLabel
Catalytic metallodrugs targeting HCV IRES RNA.
@en
Catalytic metallodrugs targeting HCV IRES RNA.
@nl
P2860
P356
P1476
Catalytic metallodrugs targeting HCV IRES RNA.
@en
P2093
Seth Bradford
P2860
P304
P356
10.1039/C2CC17377H
P407
P577
2012-02-16T00:00:00Z